Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival

Table 3 Hematological parameters before and after initial PRRT

	Baseline (mean ± SD)	n=	After 4 Cycles	Difference (%)	p-value (paired t-test)
WBC (10³/μl)	6.59 ± 2.12	35	4.48 ± 1.29	− 32.0	< 0.001
Erythrocytes (10⁶/μl)	4.48 ± 0.63	35	4.11 ± 0.54	−8.3	< 0.001
HB (g/dl)	13.43 ± 2.81	35	13.17 ± 1.40	− 1.9	= 0.506
PLT count (10³/μl)	254.86 ± 110.57	35	167.71 ± 50.62	−34.2	< 0.001

ISSN: 1471-2407